162 related articles for article (PubMed ID: 11389502)
1. Counterpoint: alternative trial designs for antifungal drugs--time to talk.
Powers JH
Clin Infect Dis; 2001 Jul; 33(1):107-9. PubMed ID: 11389502
[No Abstract] [Full Text] [Related]
2. Need for alternative trial designs and evaluation strategies for therapeutic studies of invasive mycoses.
Rex JH; Walsh TJ; Nettleman M; Anaissie EJ; Bennett JE; Bow EJ; Carillo-Munoz AJ; Chavanet P; Cloud GA; Denning DW; de Pauw BE; Edwards JE; Hiemenz JW; Kauffman CA; Lopez-Berestein G; Martino P; Sobel JD; Stevens DA; Sylvester R; Tollemar J; Viscoli C; Viviani MA; Wu T
Clin Infect Dis; 2001 Jul; 33(1):95-106. PubMed ID: 11389501
[TBL] [Abstract][Full Text] [Related]
3. Clinical trials and rare diseases.
Lagakos SW
N Engl J Med; 2003 Jun; 348(24):2455-6. PubMed ID: 12802033
[No Abstract] [Full Text] [Related]
4. Issues related to the design and interpretation of clinical trials of salvage therapy for invasive mold infection.
Almyroudis NG; Kontoyiannis DP; Sepkowitz KA; DePauw BE; Walsh TJ; Segal BH
Clin Infect Dis; 2006 Dec; 43(11):1449-55. PubMed ID: 17083020
[TBL] [Abstract][Full Text] [Related]
5. Combination therapy for invasive mycoses: evaluation of past clinical trial designs.
Sobel JD
Clin Infect Dis; 2004 Oct; 39 Suppl 4():S224-7. PubMed ID: 15546122
[TBL] [Abstract][Full Text] [Related]
6. Combination antifungal therapy.
Patterson TF
Pediatr Infect Dis J; 2003 Jun; 22(6):555-6. PubMed ID: 12799514
[No Abstract] [Full Text] [Related]
7. Mortality rates in comparative trials of formulations of amphotericin B.
Frothingham R
Clin Infect Dis; 2001 Aug; 33(4):582-3. PubMed ID: 11462201
[No Abstract] [Full Text] [Related]
8. Considerations in clinical trials of combination antifungal therapy.
Powers JH
Clin Infect Dis; 2004 Oct; 39 Suppl 4():S228-35. PubMed ID: 15546123
[TBL] [Abstract][Full Text] [Related]
9. Salvage therapy trials in invasive fungal disease: challenges and opportunities.
Powers JH
Clin Infect Dis; 2006 Dec; 43(11):1456-60. PubMed ID: 17083021
[No Abstract] [Full Text] [Related]
10. Preventing fungal infections in chronic granulomatous disease.
Franzblau MJ
N Engl J Med; 2003 Sep; 349(12):1190-1; author reply 1190-1. PubMed ID: 14503545
[No Abstract] [Full Text] [Related]
11. Issues in clinical trials of prophylaxis of fungal infections.
Powers JH
Clin Infect Dis; 2004 Oct; 39 Suppl 4():S211-7. PubMed ID: 15546120
[TBL] [Abstract][Full Text] [Related]
12. The design of clinical trials that evaluate antifungal prophylaxis and combination therapy: introduction and overview.
Rex JH; Wingard JR; Wenzel R; Herbrecht R; Sobel J; Edwards JE
Clin Infect Dis; 2004 Oct; 39 Suppl 4():S165-9. PubMed ID: 15546112
[TBL] [Abstract][Full Text] [Related]
13. Selecting antifungal agents for the treatment of invasive fungal infections in patients with renal failure.
Moudgal VV; Sobel JD
Curr Opin Investig Drugs; 2004 Aug; 5(8):873-8. PubMed ID: 15600244
[TBL] [Abstract][Full Text] [Related]
14. Current practice of antifungal prophylaxis and treatment in immunocompromised children and adults with malignancies: a single centre approach.
Lehrnbecher T; Mousset S; Sörensen J; Böhme A
Mycoses; 2009 Mar; 52(2):107-17. PubMed ID: 18983431
[TBL] [Abstract][Full Text] [Related]
15. Posaconazole: new indications. Prevention of invasive mycosis and treatment of oropharyngeal candidiasis: no therapeutic advantage.
Prescrire Int; 2008 Dec; 17(98):233. PubMed ID: 19422144
[No Abstract] [Full Text] [Related]
16. Design of the "Thorough QT Study".
Darpo B; Sager P
Clin Pharmacol Ther; 2008 Apr; 83(4):529; author reply 530. PubMed ID: 18043696
[No Abstract] [Full Text] [Related]
17. Forum report: issues in clinical trials of empirical antifungal therapy in treating febrile neutropenic patients.
Bennett JE; Powers J; Walsh T; Viscoli C; de Pauw B; Dismukes W; Galgiani J; Glauser M; Herbrecht R; Kauffman C; Lee J; Pappas P; Rex J; Verweij P
Clin Infect Dis; 2003 Apr; 36(Suppl 3):S117-22. PubMed ID: 12679895
[TBL] [Abstract][Full Text] [Related]
18. Forum report: issues in the evaluation of diagnostic tests, use of historical controls, and merits of the current multicenter collaborative groups.
Bennett JE; Kauffman C; Walsh T; de Pauw B; Dismukes W; Galgiani J; Glauser M; Herbrecht R; Lee J; Pappas P; Powers J; Rex J; Verweij P; Viscoli C
Clin Infect Dis; 2003 Apr; 36(Suppl 3):S123-7. PubMed ID: 12679896
[TBL] [Abstract][Full Text] [Related]
19. Antifungal prophylaxis in solid-organ transplant recipients: considerations for clinical trial design.
Singh N
Clin Infect Dis; 2004 Oct; 39 Suppl 4():S200-6. PubMed ID: 15546118
[TBL] [Abstract][Full Text] [Related]
20. Prevention and early treatment of invasive fungal infection in patients with cancer and neutropenia and in stem cell transplant recipients in the era of newer broad-spectrum antifungal agents and diagnostic adjuncts.
Segal BH; Almyroudis NG; Battiwalla M; Herbrecht R; Perfect JR; Walsh TJ; Wingard JR
Clin Infect Dis; 2007 Feb; 44(3):402-9. PubMed ID: 17205448
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
